Differences in the gastrointestinal microbiome signature in patients with chronic obstructive pulmonary disease (COPD) compared to healthy people

Peter Wark0 个研究点目标入组 100 人开始时间: 2014年12月9日最近更新: 2020年2月3日

试验速览

暂无简介。

•Adults > age 40 years with COPD GOLD grade 2 and above, confirmed by incompletely reversible airflow obstruction (post bronchodilator forced expiratory volume in one second (FEV1) <80% predicted and forced expiratory ratio (FER) <0.7 or physician confirmed COPD in patients with a reduced forced vital capacity (FVC)), and stable disease with no recent respiratory infection, acute exacerbation, or change in maintenance therapy in the previous 4 weeks.
•Participants will be classified according to their GOLD quadrant (A, B, C, D).
•Healthy controls subjects will be adults >40 years recruited from the Hunter Medical Research Institute volunteer register. Participants will have no history of cardiac or respiratory disease and have normal lung function measured by spirometry. In addition they will not have experienced a respiratory tract infection in the previous four weeks, nor used antibiotics.

•Participants will be excluded if they have received treatment with an antibiotic or oral prednisone in the last 4 weeks. This includes the regular use of antibiotics in subjects with COPD. In addition subjects with a previous history of gastrointestinal disease (GI disease), will be excluded. Subjects will also be excluded if they have a history of significant abdominal pain, bloating or diarrhoea in the previous 4 weeks. The study does not exclude current or ex-smokers.

发起方

Peter Wark